Last checked at 15 Aug 2022 15:25
ReNeuron Group plc
("ReNeuron" or the "Company")
Posting of Annual Report & Accounts
& Notice of AGM
ReNeuron Group plc (AIM: RENE), a UK-based stem cell leader in stem cell derived exosome technologies, announces that its Annual Report and Accounts for the year ended 31 March 2022 and the Notice of the 2022 Annual General Meeting ("AGM") have today been sent to shareholders and are also available on the Company's website at www.reneuron.com.
ReNeuron's AGM will be held at 09.30am on Friday 9 September 2022 at the offices of Covington and Burling LLP, Level 54, 22 Bishopsgate, London, EC2N 4BQ
At the time of publication of the notice of AGM, the Government has lifted most legal restrictions relating to public gatherings that had previously been in place due to the ongoing COVID-19 Pandemic. In line with this, the Board welcomes the opportunity to invite shareholders to attend the AGM in person Should this situation change, shareholders will be notified though our website www.reneuron.com and, where appropriate by RNS. Attendees will need to pre-register, please refer to the Notice of AGM or to your proxy card for information on how to do so.
Shareholders are encouraged to send any questions for the Chairman to info@reneuron.com at least 48 hours prior to the meeting. Where appropriate, such questions and answers will be collated and later published, together with full voting details, in the Investor Centre of the Company's website at www.reneuron.com.
ENDS
Contacts:
ReNeuron | www.reneuron.com/investors |
Iain Ross, Chairman | Via Walbrook PR |
Catherine Isted, Chief Financial Officer |
|
|
|
Liberum Capital Limited (NOMAD and Joint Broker) Phil Walker (Investment Banking) Richard Lindley (Investment Banking) Ben Cryer (Investment Banking) | +44 (0)20 3110 2000
|
| |
Allenby Capital Limited (Joint Broker) | +44 (0)20 3328 5656 |
James Reeve/George Payne (Corporate Finance) | |
Stefano Aquilino (Sales & Corporate Broking) | |
| |
Walbrook PR (Media & Investor Relations) | +44 (0)20 7933 8780 or reneuron@walbrookpr.com |
Alice Woodings | +44 (0)7407 804 654 |
About ReNeuron
ReNeuron is a UK based leader in proprietary stem cell derived exosome technologies, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.
ReNeuron's stem cell derived proprietary exosome technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Group has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
The Group has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-license both of these programmes in other territories.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com